
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan, Cansu Karakaş, Iman Doostan, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 246
Smruthi Vijayaraghavan, Cansu Karakaş, Iman Doostan, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 246
Showing 1-25 of 246 citing articles:
Targeting autophagy in cancer
Angelique Onorati, Matheus Dyczynski, Rani Ojha, et al.
Cancer (2018) Vol. 124, Iss. 16, pp. 3307-3318
Open Access | Times Cited: 787
Angelique Onorati, Matheus Dyczynski, Rani Ojha, et al.
Cancer (2018) Vol. 124, Iss. 16, pp. 3307-3318
Open Access | Times Cited: 787
Senescent Cells in Cancer Therapy: Friends or Foes?
Boshi Wang, Jaskaren Kohli, Marco Demaria
Trends in cancer (2020) Vol. 6, Iss. 10, pp. 838-857
Open Access | Times Cited: 388
Boshi Wang, Jaskaren Kohli, Marco Demaria
Trends in cancer (2020) Vol. 6, Iss. 10, pp. 838-857
Open Access | Times Cited: 388
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Shom Goel, Molly J. DeCristo, Sandra S. McAllister, et al.
Trends in Cell Biology (2018) Vol. 28, Iss. 11, pp. 911-925
Open Access | Times Cited: 387
Shom Goel, Molly J. DeCristo, Sandra S. McAllister, et al.
Trends in Cell Biology (2018) Vol. 28, Iss. 11, pp. 911-925
Open Access | Times Cited: 387
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
Nicholas C. Turner, Yuan Liu, Zhou Zhu, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 14, pp. 1169-1178
Open Access | Times Cited: 355
Nicholas C. Turner, Yuan Liu, Zhou Zhu, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 14, pp. 1169-1178
Open Access | Times Cited: 355
Targeting CDK4 and CDK6 in cancer
Shom Goel, Johann S. Bergholz, Jean J. Zhao
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 356-372
Open Access | Times Cited: 321
Shom Goel, Johann S. Bergholz, Jean J. Zhao
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 356-372
Open Access | Times Cited: 321
Lysosome biogenesis: Regulation and functions
Chonglin Yang, Xiaochen Wang
The Journal of Cell Biology (2021) Vol. 220, Iss. 6
Open Access | Times Cited: 308
Chonglin Yang, Xiaochen Wang
The Journal of Cell Biology (2021) Vol. 220, Iss. 6
Open Access | Times Cited: 308
CDK4 and CDK6 kinases: From basic science to cancer therapy
Anne Fassl, Yan Geng, Piotr Siciński
Science (2022) Vol. 375, Iss. 6577
Open Access | Times Cited: 307
Anne Fassl, Yan Geng, Piotr Siciński
Science (2022) Vol. 375, Iss. 6577
Open Access | Times Cited: 307
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey, Hee Jung An, Seung-Ki Kim, et al.
International Journal of Cancer (2018) Vol. 145, Iss. 5, pp. 1179-1188
Open Access | Times Cited: 291
Kamal Pandey, Hee Jung An, Seung-Ki Kim, et al.
International Journal of Cancer (2018) Vol. 145, Iss. 5, pp. 1179-1188
Open Access | Times Cited: 291
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Mónica Álvarez‐Fernández, Marcos Malumbres
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 514-529
Open Access | Times Cited: 283
Mónica Álvarez‐Fernández, Marcos Malumbres
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 514-529
Open Access | Times Cited: 283
Fasting-mimicking diet and hormone therapy induce breast cancer regression
Irene Caffa, V. Spagnolo, Claudio Vernieri, et al.
Nature (2020) Vol. 583, Iss. 7817, pp. 620-624
Open Access | Times Cited: 276
Irene Caffa, V. Spagnolo, Claudio Vernieri, et al.
Nature (2020) Vol. 583, Iss. 7817, pp. 620-624
Open Access | Times Cited: 276
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Theresa E. Hickey, Luke A. Selth, Kee Ming Chia, et al.
Nature Medicine (2021) Vol. 27, Iss. 2, pp. 310-320
Open Access | Times Cited: 188
Theresa E. Hickey, Luke A. Selth, Kee Ming Chia, et al.
Nature Medicine (2021) Vol. 27, Iss. 2, pp. 310-320
Open Access | Times Cited: 188
Selective Autophagy Regulates Cell Cycle in Cancer Therapy
Kai Zheng, Zhendan He, Kaio Kitazato, et al.
Theranostics (2018) Vol. 9, Iss. 1, pp. 104-125
Open Access | Times Cited: 185
Kai Zheng, Zhendan He, Kaio Kitazato, et al.
Theranostics (2018) Vol. 9, Iss. 1, pp. 104-125
Open Access | Times Cited: 185
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, et al.
Cancer Cell (2021) Vol. 39, Iss. 10, pp. 1404-1421.e11
Closed Access | Times Cited: 131
Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, et al.
Cancer Cell (2021) Vol. 39, Iss. 10, pp. 1404-1421.e11
Closed Access | Times Cited: 131
Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs
Natálie Kudlová, Juan Bautista De Sanctis, Marián Hajdúch
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4168-4168
Open Access | Times Cited: 91
Natálie Kudlová, Juan Bautista De Sanctis, Marián Hajdúch
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4168-4168
Open Access | Times Cited: 91
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C. Watt, Shom Goel
Breast Cancer Research (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 87
April C. Watt, Shom Goel
Breast Cancer Research (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 87
CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
Lisa Crozier, Reece Foy, Brandon L. Mouery, et al.
The EMBO Journal (2022) Vol. 41, Iss. 6
Open Access | Times Cited: 86
Lisa Crozier, Reece Foy, Brandon L. Mouery, et al.
The EMBO Journal (2022) Vol. 41, Iss. 6
Open Access | Times Cited: 86
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
Craig M. Goodwin, Andrew M. Waters, Jennifer E. Klomp, et al.
Cancer Research (2022) Vol. 83, Iss. 1, pp. 141-157
Open Access | Times Cited: 84
Craig M. Goodwin, Andrew M. Waters, Jennifer E. Klomp, et al.
Cancer Research (2022) Vol. 83, Iss. 1, pp. 141-157
Open Access | Times Cited: 84
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman, Sarah Alexandrou, Emma‐Kate Carson, et al.
Endocrine Related Cancer (2018) Vol. 26, Iss. 1, pp. R15-R30
Open Access | Times Cited: 142
Neil Portman, Sarah Alexandrou, Emma‐Kate Carson, et al.
Endocrine Related Cancer (2018) Vol. 26, Iss. 1, pp. R15-R30
Open Access | Times Cited: 142
The role of autophagy in resistance to targeted therapies
Luigi Mele, Vitale Del Vecchio, Davide Liccardo, et al.
Cancer Treatment Reviews (2020) Vol. 88, pp. 102043-102043
Open Access | Times Cited: 132
Luigi Mele, Vitale Del Vecchio, Davide Liccardo, et al.
Cancer Treatment Reviews (2020) Vol. 88, pp. 102043-102043
Open Access | Times Cited: 132
Cellular senescence in cancer: from mechanisms to detection
Hui‐Ling Ou, Reuben Hoffmann, Cristina González‐López, et al.
Molecular Oncology (2020) Vol. 15, Iss. 10, pp. 2634-2671
Open Access | Times Cited: 131
Hui‐Ling Ou, Reuben Hoffmann, Cristina González‐López, et al.
Molecular Oncology (2020) Vol. 15, Iss. 10, pp. 2634-2671
Open Access | Times Cited: 131
Control of the Restriction Point by Rb and p21
Justin Moser, Iain D. Miller, Dylan Carter, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 35
Open Access | Times Cited: 125
Justin Moser, Iain D. Miller, Dylan Carter, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 35
Open Access | Times Cited: 125
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du, Xiang Guo, Miao Wang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 123
Qi Du, Xiang Guo, Miao Wang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 123
Immunomodulation by anticancer cell cycle inhibitors
Giulia Petroni, Silvia C. Formenti, Selina Chen‐Kiang, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 669-679
Open Access | Times Cited: 118
Giulia Petroni, Silvia C. Formenti, Selina Chen‐Kiang, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 669-679
Open Access | Times Cited: 118
Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer
Shouping Xu, Peiyuan Wang, Jian Zhang, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 114
Shouping Xu, Peiyuan Wang, Jian Zhang, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 114